WO2002087552A3 - Androgen-mediated neuroprotection and uses thereof - Google Patents

Androgen-mediated neuroprotection and uses thereof Download PDF

Info

Publication number
WO2002087552A3
WO2002087552A3 PCT/CA2002/000668 CA0200668W WO02087552A3 WO 2002087552 A3 WO2002087552 A3 WO 2002087552A3 CA 0200668 W CA0200668 W CA 0200668W WO 02087552 A3 WO02087552 A3 WO 02087552A3
Authority
WO
WIPO (PCT)
Prior art keywords
androgens
prevention
neural
treatment
cell death
Prior art date
Application number
PCT/CA2002/000668
Other languages
French (fr)
Other versions
WO2002087552A2 (en
Inventor
Andrea Leblanc
Morrie Gelfand
Mark Trifiro
Original Assignee
Univ Mcgill
Andrea Leblanc
Morrie Gelfand
Mark Trifiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002345864A external-priority patent/CA2345864A1/en
Application filed by Univ Mcgill, Andrea Leblanc, Morrie Gelfand, Mark Trifiro filed Critical Univ Mcgill
Priority to AU2002257430A priority Critical patent/AU2002257430A1/en
Publication of WO2002087552A2 publication Critical patent/WO2002087552A2/en
Publication of WO2002087552A3 publication Critical patent/WO2002087552A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

Androgens, such as testosterone, methyltestosterone, and epitestosterone, are disclosed herein as being neuroprotective, in that they inhibit or prevent cell death or apoptosis of neural cells. A neuroprotective effect of androgens on primary cultures of human neurons with respect to serum deprivation-mediated apoptosis and amyloid beta peptide mediated neurotoxicity is described. The invention thus provides methods and uses of androgens as well as compositions and commercial packages comprising androgens for the prevention and/or treatment of neural or neurodegenerative disease and for the prevention and/or inhibition of cell death. The invention further provides methods of identifying and screening compounds for the prevention and/or treatment of neural or neurodegenerative disease.
PCT/CA2002/000668 2001-05-01 2002-04-30 Androgen-mediated neuroprotection and uses thereof WO2002087552A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002257430A AU2002257430A1 (en) 2001-05-01 2002-04-30 Androgen-mediated neuroprotection and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CA2,345,864 2001-05-01
CA002345864A CA2345864A1 (en) 2001-05-01 2001-05-01 Androgen-mediated neuroprotection and its use for prevention, treatment and study of neural disease
US29403101P 2001-05-30 2001-05-30
US60/294,031 2001-05-30
US33056701P 2001-10-25 2001-10-25
US60/330,567 2001-10-25

Publications (2)

Publication Number Publication Date
WO2002087552A2 WO2002087552A2 (en) 2002-11-07
WO2002087552A3 true WO2002087552A3 (en) 2003-10-02

Family

ID=27171527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000668 WO2002087552A2 (en) 2001-05-01 2002-04-30 Androgen-mediated neuroprotection and uses thereof

Country Status (2)

Country Link
AU (1) AU2002257430A1 (en)
WO (1) WO2002087552A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083277A1 (en) 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
WO2006026426A2 (en) 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
AU2008325211B2 (en) * 2007-11-06 2014-11-13 Signal Coordinating Therapy, Inc. Compositions and methods for treating Parkinson's disease and related disorders
US20120309728A1 (en) * 2009-12-18 2012-12-06 Catherine Grenot New steroid inhibitors of pgp for use for inhibiting multidrug resistance
WO2020247407A1 (en) * 2019-06-03 2020-12-10 Aihol Corporation Hyaluronan conjugates and uses thereof
WO2022204827A1 (en) * 2021-03-24 2022-10-06 兰州大学 Application of halcinonide and derivatives thereof for preparing drug treating and/or preventing cerebrovascular disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
JPH06100466A (en) * 1992-02-14 1994-04-12 Tsumura & Co Controlling agent for cerebroneurocytic organ lesion with stress nature
US5795883A (en) * 1993-04-13 1998-08-18 Jenapharm Gmbh Androgens and anabolic agents
WO2000010536A1 (en) * 1998-08-25 2000-03-02 Columbia Laboratories (Bermuda) Limited Extended release buccal bioadhesive tablet
WO2001072307A1 (en) * 2000-03-29 2001-10-04 The J. David Gladstone Institutes Methods of treating cognitive decline disease conditions with androgens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
JPH06100466A (en) * 1992-02-14 1994-04-12 Tsumura & Co Controlling agent for cerebroneurocytic organ lesion with stress nature
US5795883A (en) * 1993-04-13 1998-08-18 Jenapharm Gmbh Androgens and anabolic agents
WO2000010536A1 (en) * 1998-08-25 2000-03-02 Columbia Laboratories (Bermuda) Limited Extended release buccal bioadhesive tablet
WO2001072307A1 (en) * 2000-03-29 2001-10-04 The J. David Gladstone Institutes Methods of treating cognitive decline disease conditions with androgens

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199419, Derwent World Patents Index; Class B01, AN 1994-156568, XP002232575 *
FINKELSTEIN M ET AL: "COMPARATIVE STUDIES OF THE AROMATIZATION OF TESTOSTERONE AND EPI TESTOSTERONE BY HUMAN PLACENTAL AROMATASE", ENDOCRINOLOGY, vol. 108, no. 3, 1981, pages 943 - 947, XP008014327, ISSN: 0013-7227 *
GOURAS GUNNAR K ET AL: "Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 3, 1 February 2000 (2000-02-01), Feb. 1, 2000, pages 1202 - 1205, XP002232570, ISSN: 0027-8424 *
GREEN PATTIE S ET AL: "17 alpha-Estradiol exerts neuroprotective effects on SK-N-SH cells.", JOURNAL OF NEUROSCIENCE, vol. 17, no. 2, 1997, pages 511 - 515, XP002232574, ISSN: 0270-6474 *
HAMMOND JENNIFER ET AL: "Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons.", JOURNAL OF NEUROCHEMISTRY, vol. 77, no. 5, June 2001 (2001-06-01), pages 1319 - 1326, XP002232572, ISSN: 0022-3042 *
NUÑEZ J L ET AL: "Androgens reduce cell death in the developing rat visual cortex.", BRAIN RESEARCH. DEVELOPMENTAL BRAIN RESEARCH. NETHERLANDS 29 DEC 2000, vol. 125, no. 1-2, 29 December 2000 (2000-12-29), pages 83 - 88, XP001148402, ISSN: 0165-3806 *
PAPASOZOMENOS S: "The heat shock-induced hyperphosphorylation of tau is estrogen-independent and prevented by androgens: Implications for Alzheimer disease.", PROC. NATL. ACAD. SCI., vol. 94, 1997, USA, pages 6612 - 6617, XP002232571 *

Also Published As

Publication number Publication date
AU2002257430A1 (en) 2002-11-11
WO2002087552A2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
Baydas et al. Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro-and anti-apoptotic protein levels
WO2007027559A3 (en) Neuroprotective and neurorestorative methods and compositions
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
WO2003009855A3 (en) Organo-phosphorous compounds for activating gamma/delta t cells
AU2003252146A1 (en) Material compositions and related systems and methods for treating cardiac conditions
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2004032713A3 (en) Sealants for skin and other tissues
ATE398459T1 (en) USE OF NAIP OR IAP FOR THE TREATMENT AND PREVENTION OF NEURONAL DISEASES
WO2004006858A3 (en) Compounds, compositions, and methods employing same
SG163567A1 (en) Treatment of tumors
MY147247A (en) Organic compounds and their uses
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2010059004A3 (en) Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
WO2003106381A3 (en) Human adam-10 inhibitors
WO2005121778A3 (en) Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
TW268937B (en)
AU5314900A (en) Compositions and methods for inhibiting cell death
WO2008013983A3 (en) Opsin stabilizing compounds and methods of use
WO2002087552A3 (en) Androgen-mediated neuroprotection and uses thereof
AU3052799A (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
AU2003272945A1 (en) Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction
WO2003105753A3 (en) Targeted enzymes and methods of making and using targeted enzymes.
Tanaka et al. Molecular basis of 6-hydroxydopamine-induced caspase activations due to increases in oxidative stress in the mouse striatum
WO2009043858A3 (en) Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease
WO2009024991A3 (en) Antiobese compositions containing holopteleλ integrifolia extracts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP